2019 | 2017 | 2015-2016 | 2013-2012 | 2009-2011 | 2008 | 2006-2007 | 2005 | 2004 | 2003 |
Enacted January 2003
Recently revised January 9, 2019
Genomics & Informatics (Genomics Inform) is owned and published by the Korea Genome Organization (KOGO). It is published four times per year (Mar, Jun, Sep, and Dec) in an online version. Genomics & Informatics welcomes high-quality research papers presenting novel data on the topics of gene discovery, comparative genome analyses, molecular and human evolution, informatics, genome structure and function, technological innovations and applications, statistical and mathematical methods, cuttingedge genetic and physical mapping, and DNA sequencing and other reports that present data where sequence information is used to address biological concerns. The journal publishes papers based on original research that are judged after editorial review to make a substantial contribution to the understanding of any area of genomics or informatics. Only manuscripts written in English under the Genomics & Informatics author guidelines are accepted. Genomics & Informatics follows the open access journal policy. All of the content of Genomics & Informatics is freely available online. Digital files can be read, downloaded, and printed without charge. Manuscripts for submission to Genomics & Informatics should be prepared according to the following instructions. Genomics & Informatics follows the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals (http://www.icmje.org) from ICMJE and Principles of Transparency and Best Practice in Scholarly Publishing (joint statement by COPE, DOAJ, WAME, and OASPA; (http://doaj.org/bestpractice) if otherwise not described below. |
||||||||||||||||||||||||||||||||||||||||
Research and publication ethics | ||||||||||||||||||||||||||||||||||||||||
For the policies on research and publication ethics that are not stated in these instructions, the Good Publication Practice Guidelines for Medical Journals (https://www.kamje.or.kr/board/view?b_name=bo_publication&bo_id=7) and the Guidelines on Good Publication(http://publicationethics.org/resources/guidelines) can be applied. The Editor-in-Chief reserves the right to reject manuscripts that do not comply with the below requirements. The author will be held responsible for false statements or failure to fulfill the below requirements. Statement of Informed Consent: Copies of written informed consent and Institutional Review Board (IRB) approval for clinical research should be kept. If necessary, the editor or reviewers may request copies of these documents to resolve questions about IRB approval or study conduct. Statement of Human and Animal Rights: All human investigations must be conducted according to the principles expressed in the Declaration of Helsinki. All studies involving animals must state that the guidelines for the use and care of laboratory animals of the authors’ institution, or of any national law, were followed. Registration of clinical trial research: Any research that deals with a clinical trial should be registered with the primary national clinical trial registry site, such as the Korea Clinical Research Information Service (CRiS, http://cris.nih.go.kr), other primary national registry sites accredited by the World Health Organization (http://www.who.int/ictrp/network/primary/en/), or ClinicalTrials.gov (http://clinicaltrials.gov/), a service of the United States National Institutes of Health. Authorship: Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data, and/or analysis and interpretation of data; 2) drafting the article or revising it critically for important intellectual content; 3) final approval of the version to be published; and 4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Every author should meet all of these four conditions. After the initial submission of a manuscript, any changes whatsoever in authorship (adding author(s), deleting author(s), or re-arranging the order of authors) must be explained by a letter to the editor from the authors concerned. This letter must be signed by all authors of the paper. Copyright assignment must also be completed by every author. Corresponding author and first author: It does allow multiple corresponding authors for one article. Only one author should correspond with the editorial office. It does accept notice of equal contribution for the first author when the study was clearly performed by co-first authors. Correction of authorship after publication: It does not correct authorship after publication unless a mistake has been made by the editorial staff. Authorship may be changed before publication but after submission when an authorship correction is requested by all of the authors involved with the manuscript. Conflict of Interest Statement: The corresponding author must inform the editor of any potential conflicts of interest that could influence the authors’ interpretation of the data. Examples of potential conflicts of interest are financial support from or connections to pharmaceutical companies, political pressure from interest groups, and academically related issues. In particular, all sources of funding applicable to the study should be explicitly stated. As a guideline, any affiliation associated with a payment or financial benefit exceeding $10,000 per annum or 5% ownership of a company or research funding by a company with related interests would constitute a conflict that must be declared. This policy applies to all submitted research manuscripts and review material. Originality and Duplicate Publication: No part of the accepted manuscript should be duplicated in any other scientific journal without the permission of the Editorial Board. If duplicate publication or plagiarism related to the papers of this journal is detected, the authors will be announced in the journal, their institutes will be informed, and the authors will be penalized. All submitted manuscripts are screened by CrossCheck (Similarity Check), a plagiarism detection program provided by iThenticate. The authors assure that no substantial part of the work has been published or is being considered for publication elsewhere. When any of the results is to appear in another journal, details must be submitted to the Editor-in-Chief, together with a copy of the other paper(s) and the expected date(s) of publication. Secondary Publication: It is possible to republish manuscripts if the manuscripts satisfy the condition of secondary publication of the Uniform Requirements for Manuscripts Submitted to Biomedical Journals by the International Committee of Medical Journal Editors (ICMJE), available from http://www.icmje.org/. These are:
|
||||||||||||||||||||||||||||||||||||||||
Preparation of manuscripts | ||||||||||||||||||||||||||||||||||||||||
General requirement Authors are recommended to keep the length of papers below 10 printed pages (30 typed pages of manuscript, including figures and tables) for original articles, four printed pages for research communications, and two printed pages (approximately 1,400 words or 1,000 words plus one figure) for application notes. All sections of the typescript should be double-spaced on one side of A4 paper (210 × 297 mm), and all pages must be numbered in order. Manuscript type
• Original articles
Title: The title page should include (1) the full names of all authors with their Open Researchers and Contributors ID (ORCID), and the name(s) and address(es) of the institution(s) at which the work was carried out; (2) the telephone and fax numbers, and the E-mail address of the corresponding author; and (3) a running title of no more than 50 characters, including spaces. Place an asterisk (*) after the corresponding author.
(1) Introduction: The paper begins with an introduction without subheadings that reviews the literature and states and justifies the purpose of the research.
(2) Methods: This section should contain sufficient detail so that all procedures can be repeated, in conjunction with the cited references. The manufacturer and model number should be stated in this section—for example, as Sigma Chemical Co. (St. Louis, MO, USA). (3) Results: This section should describe the results of the experiments. Extensive interpretation should be reserved for the Discussion section. The results should be presented as concisely as possible. Footnotes should not be used and will be transferred to the text. Gene symbols should be italicized; protein products are not italicized. (4) Discussion: This section should provide an interpretation of the results in relation to previously published work and to the experimental system at hand. The Results and Discussion may be combined. (5) Acknowledgments: Information concerning the sources of financial support should be included in the acknowledgments.
Authors’ contribution: If the number of authors is equal to or greater than two, the authors’ roles should be described according to their specific role. Genomics & Informatics participates in the CRediT standard for author contributions. The contributions of all authors must be described using the CRediT Taxonomy of author roles. For each of the categories below, please enter the initials of the authors who contributed in that category. If listing more than one author in a category, separate each set of initials with a space. If no one contributed in a category, you may leave that box blank. The corresponding author is responsible for completing this information at submission, and it is expected that all authors will have reviewed, discussed, and agreed to their individual contributions ahead of this time.
Journal article
- Park J, Lappe M, Teichmann SA. Mapping protein family interactions: intramolecular and intermolecular protein family interaction repertoires in the PDB and yeast. J Mol Biol 2001;307:929-938. - Cho SM, Jung SH, Chung YJ. A variant in RUNX3 is associated with the risk of ankylosing spondylitis in Koreans. Genomics Inform 2017;15:65-68. - Thomas PD, Campbell MJ, Kejariwal A, Mi H, Karlak B, Daverman R, et al. PANTHER: a library of protein families and subfamilies indexed by function. Genome Res 2003;13:2129-2141. Books - Cowan WM, Jessell TM, Zipursky SL. Molecular and Cellular Approaches to Neural Development. New York: Oxford University Press, 1997. Book sections - Sorenson PW, Caprio JC. Chemoreception. In: The Physiology of Fishes (Evans DH, ed.). Boca Raton: CRC Press, 1998. pp. 375-405. Online document - Puniyani AR, Lukose RM. Growing random networks under constraints. Ithaca: Cornell University Library, 2001. Accessed 2011 Oct 3. Available from: http://xxx.lanl.gov/abs/cond-mat/0107391. Conference paper - Han H. Nonnegative principle component analysis for mass spectral serum profiles and biomarker discovery. In: The 8th Asia-Pacific Bioinformatics Conference (Parida L, Myers G, eds.), 2010 Jan 18-21, Bangalore. Dissertation/Thesis - Hwang KB. Hierarchical probabilistic graphical models for large-scale data analysis. Ph.D. Dissertation. Seoul: Seoul National University, 2005.
Tables and figures: Figure legends and tables should be included in the submitted manuscript as separate sections and should be formatted following the style of the journal. Each figure legend should have a brief, separate title that describes the entire figure without citing specific panels. The manuscript should be submitted with a set of figures of sufficient quality for reviewers to judge the data. All figures may be provided in color for the electronic version of the journal, even if the print version is in black and white. Figures will be printed in color only when in the reviewers' opinions the color is essential.
File sizes must be as small as possible, for quick downloading. Recommended specifics are:
Please seek advice from the editorial office before sending files larger than our recommended size to avoid delays in publication. |
||||||||||||||||||||||||||||||||||||||||
Submission of Manuscript | ||||||||||||||||||||||||||||||||||||||||
The manuscript should be submitted in MS Word file format. The recommended font is Times New Roman with a 11-point font size. All manuscripts must be submitted online through the Genomics & Informatics e-submission system at http://submit.genominfo.org. Any questions concerning manuscript submission should be directed to: Editor, Genomics & Informatics, Korea Genome Organization, The Korean Federation of Science and Technology Societies, Room No. 806, 193 Mallijae-ro, Jung-gu, Seoul 04501, Korea (http://www.kogo.or.kr, Tel: +82-2-558-9394, Fax: +82-2-558-9434, E-mail: kogo@kogo.or.kr). | ||||||||||||||||||||||||||||||||||||||||
Peer review and revision of manuscripts | ||||||||||||||||||||||||||||||||||||||||
Peer review A manuscript is generally reviewed by at least two peer reviewers qualified to evaluate the manuscript. It is a single blind peer review. An initial decision will normally be made within one month of receipt of a manuscript. A manuscript that has been published or of which a substantial portion has been published elsewhere will not be accepted. The Editor-in-Chief is responsible for final decisions regarding the acceptance of a peer-reviewed paper. Manuscript revision When a manuscript is returned to the corresponding author for revision, the reviewed manuscript must be re-submitted within one month, unless the authors request an extension. A galley proof and reprint order form will be sent to the corresponding author. The corresponding author is responsible for communicating with the other authors about revisions and final approval of the proofs. The first proofreading is the author’s responsibility, and the proof should be returned within three days from the date of receipt. |
||||||||||||||||||||||||||||||||||||||||
Copyrights, open access policy and open data policy | ||||||||||||||||||||||||||||||||||||||||
Copyright The regulations for acceptance of a manuscript for publication automatically include the consent of the author(s) to transfer the copyright or license to KOGO. Authors should complete a Copyright Agreement Form (CAF) at the time of proofreading. The corresponding author can sign on behalf of any co-authors. The CAF can be obtained from the editorial office. Acceptance of the agreement will ensure full copyright protection and help to disseminate the article to the widest possible readership in print and electronic formats. The authors are responsible for obtaining permission to reproduce copyrighted material from other sources Open access policy Genomics & Informatics is an open access journal. Articles are distributed under the terms of the Creative Commons Attribution license (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited for non-commercial purposes. To use the tables or figures of Genomics & Informatics in other periodicals, books, or media for scholarly, educational, or even commercial purposes, the process of permission request to the Publisher is not necessary. This is in accordance with the Budapest Open Access Initiative definition of open access. It also follows the open access policy of PubMed Central at the United States National Library of Medicine (http://www.ncbi.nlm.nih.gov/pmc/). All of the content of the journal is available immediately upon publication without an embargo period. Archiving policy It is accessible without barrier from Korea Citation Index (https://kci.go.kr), National Library of Korea (http://nl.go.kr), or PubMed Central (https://www.ncbi.nlm.nih.gov/pmc/journals/1928/) in the event a journal is no longer published. Deposit policy (Self-archiving policy) according to Sherpa/Romeo (http://www.sherpa.ac.uk/): Author can not archive pre-print (i.e., pre-refereeing). Author can archive post-print (i.e., final draft post-refereeing).
ICMJE, International Committee of Medical Journal Editors. aThese examples are meant to illustrate a range of, but not all, data sharing options. Detailed Description of Use of Articles of Genomics & Informatics Reader benefit: Publisher applies the Creative Commons Attribution Non-Commercial license to works it publishes and allows free immediate access to, and unrestricted reuse of, original works of all types. Reuse benefit: Publisher applies the Creative Commons Attribution Non-Commercial license to works it publishes and allows free immediate access to, and unrestricted reuse of, original works of all types. Copyrights: Publisher applies the Creative Commons Attribution Non-Commercial license to works it publishes. Under this license, although publisher retains ownership of the copyright for content, it allows anyone to download, reuse, reprint, modify, distribute, and/or copy the content. Author posting benefit: Publisher applies the Creative Commons Non-Commercial Attribution license to works it publishes. Under this license, although publisher retains ownership of the copyright for content, it allows anyone, including author, to download, reuse, reprint, modify, distribute, and/or copy the content. Automatic Posting: Publisher immediately deposits the accepted articles in PubMed Central (http://pubmedcentral.org/) and journal homepage (https://genominfo.org/) upon publication. Machine readability: Genomics & Informatics articles can be accessed programmatically through PubMed Central or Europe PMC's RESTful Web Service (https://europepmc.org/RestfulWebService). For inquiries, please contact editorial office, as below: |
||||||||||||||||||||||||||||||||||||||||
Article processing charge | ||||||||||||||||||||||||||||||||||||||||
Neither page charge, article processing fee nor submission fee will be applied since 2019. It is the platinum open access journal.
Contact address
Editorial office |